¹«¼¼Æ÷ PA ¹é½Å(Èí¼öÇü źÀú±Õ ¹é½Å(AVA), ħÀüÇü źÀú±Õ ¹é½Å(AVP))
»ý¹é½Å
Á¦6Àå źÀú±Õ ¹é½Å ¼¼°è ½ÃÀå ºÐ¼® : ¿ëµµº°
°³¿ä : ¿ëµµº°
ºÐ¼® ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® : ¿ëµµº°
µ¿¹°¿ë
Àΰ£¿ë
Á¦7Àå źÀú±Õ ¹é½Å ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
°³¿ä: ÃÖÁ¾ ¿ëµµº°
ºÐ¼® ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
µ¿¹° º´¿ø ¹× Áø·á¼Ò
º´¿ø ¹× Áø·á¼Ò
±âŸ
Á¦8Àå źÀú±Õ ¹é½Å ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°
Àü¸Á : Áö¿ªº°
¼Ò°³
ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
ºÏ¹Ì : ºÎ¹®º°
ºÏ¹Ì : ±¹°¡º°
¹Ì±¹
ij³ª´Ù
¸ß½ÃÄÚ
À¯·´ÀÇ ¸ÅÃ⠺м®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
À¯·´ : ºÎ¹®º°
À¯·´: ±¹°¡º°
¿µ±¹
ÇÁ¶û½º
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃâºÐ¼®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
Áß±¹
Àεµ
ÀϺ»
Çѱ¹
È£ÁÖ
µ¿³²¾Æ½Ã¾Æ
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸ÅÃ⠺м®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
Æä·ç
Ä¥·¹
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÅÃ⠺м®
°³¿ä, ½ÇÀû°ú ¿¹Ãø
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«: ±¹°¡º°
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
À̽º¶ó¿¤
³²¾ÆÇÁ¸®Ä«
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå źÀú±Õ ¹é½Å ±â¾÷°æÀï ±¸µµ
źÀú±Õ ¹é½Å ½ÃÀå °æÀï
Á¦ÈÞ/Çù·Â/ÇÕÀÇ
ÇÕº´ ¹× Àμö
½ÅÁ¦Ç° Ãâ½Ã
±âŸ °³¹ß
Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
½ÃÀå ÁýÁßµµ
Altimmune Inc.
Agrovet
Bayer AG
Bavarian Nordic
Biogenesis Bago SA
Ceva Sante Animale
Colondo Serum Company
Emergent BioSolutions
Elusys Therapeutics Inc.
Indian Immunologicals Ltd.
Intervac(PVT) Ltd
JOVAC
Merck Co Inc.
Proton Biopharma Ltd
JHS
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
The global demand for Anthrax Vaccine Market is presumed to reach the market size of nearly USD 28.16 Billion by 2032 from USD 16.73 Billion in 2023 with a CAGR of 5.96% under the study period 2024-2032.
The anthrax vaccine is a biological preparation that provides immunity against Bacillus anthracis, which causes anthrax. It is primarily used for individuals at high risk of exposure, such as military personnel, laboratory workers, and individuals handling animal products. The vaccine targets the immune system to generate antibodies against the bacterium's protective antigen, thereby providing defense against infection. It is a crucial component in biodefense and occupational health programs.
MARKET DYNAMICS
The persistent threat of bioterrorism and biological warfare, coupled with the potential for natural outbreaks of anthrax, underscores the critical importance of anthrax vaccination as a public health preparedness measure. This heightened awareness of anthrax as a potential biosecurity threat drives government agencies and defense organizations to stockpile anthrax vaccines and invest in vaccination programs, bolstering market demand. Advancements in vaccine development and manufacturing technologies have led to the development of next-generation anthrax vaccines with improved safety profiles, enhanced efficacy, and reduced dosage regimens, driving market adoption and expansion. Additionally, increasing government funding and research grants for biodefense initiatives and emerging infectious diseases stimulate market growth by supporting vaccine research and development efforts.
Moreover, expanding global travel and trade networks increase the risk of anthrax transmission and dissemination, driving demand for anthrax vaccines in high-risk regions and among at-risk populations, such as military personnel, first responders, and laboratory workers. Furthermore, strategic partnerships and collaborations between pharmaceutical companies, government agencies, and research institutions facilitate vaccine production scalability, regulatory approvals, and global distribution, fostering market growth. However, potential side effects and limited awareness may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anthrax Vaccine. The growth and trends of Anthrax Vaccine industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Anthrax Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Anthrax Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anthrax Vaccine market include Altimmune Inc., Agrovet, Bayer AG, Bavarian Nordic, Biogenesis Bago SA, Ceva Sante Animale, Colondo Serum Company, Emergent BioSolutions, Elusys Therapeutics Inc., Indian Immunologicals Ltd., Intervac (PVT) Ltd, JOVAC, Merck Co Inc., Proton Biopharma Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.2 Market Attractiveness Analysis By Application
3.7.3 Market Attractiveness Analysis By End-use
3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY TYPE
5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Cell Free PA Vaccine (Anthrax Vaccine Absorbed (AVA), Anthrax Vaccine Precipitated (AVP)) Historic and Forecast Sales By Regions
5.4. Live Attenuated Vaccine Historic and Forecast Sales By Regions
6. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY APPLICATION
6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Veterinary Use Historic and Forecast Sales By Regions
6.4. Human Use Historic and Forecast Sales By Regions
7. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY END-USE
7.1. Overview By End-use
7.2. Historical and Forecast Data Analysis By End-use
7.3. Veterinary Hospitals & Clinics Historic and Forecast Sales By Regions
7.4. Hospital & Clinics Historic and Forecast Sales By Regions
7.5. Other Historic and Forecast Sales By Regions
8. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
8.3.1 Overview, Historic and Forecast Data Sales Analysis
8.3.2 North America By Segment Sales Analysis
8.3.3 North America By Country Sales Analysis
8.3.4 United States Sales Analysis
8.3.5 Canada Sales Analysis
8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
8.4.1 Overview, Historic and Forecast Data Sales Analysis
8.4.2 Europe By Segment Sales Analysis
8.4.3 Europe By Country Sales Analysis
8.4.4 United Kingdom Sales Analysis
8.4.5 France Sales Analysis
8.4.6 Germany Sales Analysis
8.4.7 Italy Sales Analysis
8.4.8 Russia Sales Analysis
8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
8.5.1 Overview, Historic and Forecast Data Sales Analysis
8.5.2 Asia Pacific By Segment Sales Analysis
8.5.3 Asia Pacific By Country Sales Analysis
8.5.4 China Sales Analysis
8.5.5 India Sales Analysis
8.5.6 Japan Sales Analysis
8.5.7 South Korea Sales Analysis
8.5.8 Australia Sales Analysis
8.5.9 South East Asia Sales Analysis
8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
8.6.1 Overview, Historic and Forecast Data Sales Analysis
8.6.2 Latin America By Segment Sales Analysis
8.6.3 Latin America By Country Sales Analysis
8.6.4 Brazil Sales Analysis
8.6.5 Argentina Sales Analysis
8.6.6 Peru Sales Analysis
8.6.7 Chile Sales Analysis
8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
8.7.1 Overview, Historic and Forecast Data Sales Analysis
8.7.2 Middle East & Africa By Segment Sales Analysis
8.7.3 Middle East & Africa By Country Sales Analysis
8.7.4 Saudi Arabia Sales Analysis
8.7.5 UAE Sales Analysis
8.7.6 Israel Sales Analysis
8.7.7 South Africa Sales Analysis
8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ANTHRAX VACCINE COMPANIES
9.1. Anthrax Vaccine Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10. COMPANY PROFILES OF ANTHRAX VACCINE INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Altimmune Inc.
10.3.1 Company Overview
10.3.2 Company Revenue
10.3.3 Products
10.3.4 Recent Developments
10.4. Agrovet
10.4.1 Company Overview
10.4.2 Company Revenue
10.4.3 Products
10.4.4 Recent Developments
10.5. Bayer AG
10.5.1 Company Overview
10.5.2 Company Revenue
10.5.3 Products
10.5.4 Recent Developments
10.6. Bavarian Nordic
10.6.1 Company Overview
10.6.2 Company Revenue
10.6.3 Products
10.6.4 Recent Developments
10.7. Biogenesis Bago SA
10.7.1 Company Overview
10.7.2 Company Revenue
10.7.3 Products
10.7.4 Recent Developments
10.8. Ceva Sante Animale
10.8.1 Company Overview
10.8.2 Company Revenue
10.8.3 Products
10.8.4 Recent Developments
10.9. Colondo Serum Company
10.9.1 Company Overview
10.9.2 Company Revenue
10.9.3 Products
10.9.4 Recent Developments
10.10. Emergent BioSolutions
10.10.1 Company Overview
10.10.2 Company Revenue
10.10.3 Products
10.10.4 Recent Developments
10.11. Elusys Therapeutics Inc.
10.11.1 Company Overview
10.11.2 Company Revenue
10.11.3 Products
10.11.4 Recent Developments
10.12. Indian Immunologicals Ltd.
10.12.1 Company Overview
10.12.2 Company Revenue
10.12.3 Products
10.12.4 Recent Developments
10.13. Intervac (PVT) Ltd
10.13.1 Company Overview
10.13.2 Company Revenue
10.13.3 Products
10.13.4 Recent Developments
10.14. JOVAC
10.14.1 Company Overview
10.14.2 Company Revenue
10.14.3 Products
10.14.4 Recent Developments
10.15. Merck Co Inc.
10.15.1 Company Overview
10.15.2 Company Revenue
10.15.3 Products
10.15.4 Recent Developments
10.16. Proton Biopharma Ltd
10.16.1 Company Overview
10.16.2 Company Revenue
10.16.3 Products
10.16.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies